Lapping up
Select biotech/pharma names showing strength following ESMO:
- CLVS +11.3%, CRDF +9%, IMTX +8.3%, IDYA +8%, LYRA +5.7%, PNT +5.7%, EWTX +4.7%, CNCE +3.6%, DCPH +3.2%, VCYT +2.6%, SWTX +2.3%, IMAB +2.3%, PBYI +1.8%, AZN +1.1%, NVS +0.9%, MRK +0.8%, EXAS +0.8%, BGNE +0.8%, .
Other news:
- SPPI +15.8% (receives FDA approval for ROLVEDON injection; expects to launch product in Q4)
- BMY +8.1% (receives FDA approval for Sotyktu)
- XL +5.1% (completes transformational acquisition of Spruce Power)
- EGLX +4.7% (signed a media sponsorship deal with Hulu + Live TV the premium streaming destination as the first official media sponsor of NFL Tuesday Night Gaming)
- CNTA +4.5% (Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101)
- FSM +2.8% (extends gold mineralization at Sunbird and identifies new regional prospects at Séguéla)
- ACAD +2.6% (receives acceptance from FDA for NDA of Trofinetide)
- OXY +1.7% (Berkshire Hathaway discloses 26.8% stake up from 20.28% previously)
- LTH +1.4% (closes on $200 million in sale-leaseback transactions)
- CSSE +1% (files for 7745453 share common stock offering by selling shareholders relates to warrants)
Analyst comments:
- APA +2.7% (upgraded to Buy from Neutral at Citigroup)
- CNI +2% (upgraded to Buy from Neutral at BofA Securities)
- UNP +1.9% (upgraded to Buy from Neutral at BofA Securities)
- CP +1.5% (upgraded to Buy from Neutral at BofA Securities)
